Reported Earnings • May 14
First quarter 2026 earnings released: CA$0.002 loss per share (vs CA$0.001 loss in 1Q 2025) First quarter 2026 results: CA$0.002 loss per share (further deteriorated from CA$0.001 loss in 1Q 2025). Revenue: CA$8.96m (down 17% from 1Q 2025). Net loss: CA$867.0k (loss widened 124% from 1Q 2025). Revenue is forecast to grow 2.0% p.a. on average during the next 2 years, compared to a 7.7% growth forecast for the Pharmaceuticals industry in Canada. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • May 08
MediPharm Labs Corp. to Report Q1, 2026 Results on May 13, 2026 MediPharm Labs Corp. announced that they will report Q1, 2026 results Pre-Market on May 13, 2026 Announcement • Apr 29
MediPharm Labs Corp. Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling MediPharm Labs Corp. the implementation of the U.S. final order rescheduling certain cannabis products from Schedule I to Schedule III of the Controlled Substances Act. The Order took effect April 22, 2026. It recognizes the medical use of cannabis and is anticipated to materially reduce barriers to U.S. clinical research and pharmaceutical development. MediPharm Labs is well positioned to benefit from this change through its FDA site registration, DEL, proven experience supplying clinical trial materials to the United States, and established presence in the world’s most regulated medical cannabis markets. Reclassifying cannabis to Schedule III removes barriers that have long limited U.S. clinical trials. Researchers publish thousands of peer-reviewed cannabis studies annually, yet full clinical trials have remained scarce due to Schedule I restrictions and the lack of federally compliant cannabis supply. The Order is expected to accelerate U.S. research by enabling access to standardized medical-grade cannabis from registered suppliers. For MediPharm Labs, this could mean an expanded pipeline of U.S. researchers and pharmaceutical companies advancing clinical trials and evaluating compliant active pharmaceutical ingredient (“API”) suppliers. The Order also creates a clearer regulatory pathway for FDA-approved drug products containing cannabis, which is directly aligned with MediPharm Labs pharmaceutical manufacturing strategy. MediPharm Labs completed its first shipment of pharmaceutical cannabis product to the United States in 2023 and has made additional shipments in subsequent years. These shipments were completed under Schedule I classification, which required the Company to navigate the most restrictive federal controls applied to any substance under U.S. law, leveraging its U.S. Food and Drug Administration (“FDA”) site registration and U.S. DEA import permits. MediPharm Labs has supplied product for over 10 active clinical trials, including the U.S. National Institutes of Health funded LiBBY study with the Keck School of Medicine of University of Southern California. To the Company’s knowledge, this was the first Phase 2 clinical trial of its kind with API sourced from a Canadian cannabis producer. With Schedule III now in effect, the regulatory pathway MediPharm Labs has already successfully navigated may become less restrictive for future U.S. shipments. With Schedule III now in effect for FDA-approved cannabis drug products and state-licensed medical cannabis, institutional investors who were previously restricted by “Schedule I trafficking” clauses may now be able to consider research-oriented cannabis companies. This could result in increased interest in pharmaceutical cannabis companies, including MediPharm Labs, as regulatory barriers evolve. There could also be renewed interest in research investments from pharmaceutical firms that previously avoided cannabis due to its previously higher-risk classification. 
